TNS Healthcare merges into KantarHealth

Share this article:

WPP formally launched KantarHealth, an amalgam of four companies that bundles global research with consulting capabilities.

The announcement follows WPP's acquisition of TNS in October 2008, and combines TNS Healthcare with Consumer Health Sciences, MattsonJack and Ziment. KantarHealth is led by co-CEOs Lynnette Cooke, formerly CEO at Ziment, and Elaine Riddell, previously the CEO at TNS Healthcare. Richard Martin, formerly COO at MattsonJack, is COO at KantarHealth.

According to Ilene Siegalovsky, SVP, global strategic marketing, the legacy companies' names will be phased out and will operate exclusively under the KantarHealth banner. With US headquarters in New York City, Siegalovsky said the company will be “managed globally,” with over 40 offices spread across the Americas, Europe, Asia-Pacific, the Middle East and Africa.

Siegalovsky said the company works with “literally every pharmaceutical and biotech company” in some capacity, including all of the top 10 pharmas. Mixing a consulting practice with research enables KantarHealth to provide practical business advice on top of raw information, said Siegalovsky, citing complaints about research groups in the past. “They provide great information, but it's not always particularly applicable. We organize around the consultancy…to focus on a specific aspect of a company's business,” she said.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what ...

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...